|
|
| | GSK5959 Basic information |
| Product Name: | GSK5959 | | Synonyms: | GSK5959;Benzamide, N-[2,3-dihydro-1,3-dimethyl-2-oxo-6-(1-piperidinyl)-1H-benzimidazol-5-yl]-2-methoxy-;CS-1636;GSK-5959;GSK5959;N-[2,3-Dihydro-1,3-dimethyl-2-oxo-6-(1-piperidinyl)-1H-benzimidazol-5-yl]-2-methoxybenzamide;BRPF1-IN-3;BRPF3,GSK5959,bromodomain,Inhibitor,inhibit,BRD1,BRPF1,Epigenetic Reader Domain,GSK-5959,GSK 5959,BRPF2,epigenetics | | CAS: | 901245-65-6 | | MF: | C22H26N4O3 | | MW: | 394.47 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 901245-65-6.mol |  |
| | GSK5959 Chemical Properties |
| Boiling point | 527.3±50.0 °C(Predicted) | | density | 1.263±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 13 mg/mL (32.96 mM; Need ultrasonic and warming) | | form | Powder | | pka | 13.06±0.20(Predicted) |
| | GSK5959 Usage And Synthesis |
| Description | GSK 5959 exhibits >100-fold selectivity for BRPF1 (IC50 = 80 nM) over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. Inhibits BRPF1 interaction with histone H3.3, which is involved in the epigenetic regulation of gene expression and have been implicated in human cancer. | | Uses | GSK5959 is as elective BRPF1 bromodomain inhibitor. | | storage | Store at +4°C |
| | GSK5959 Preparation Products And Raw materials |
|